Scarica l'app Stockscreener
159.99
1.90%
-3.10
Dopo l'orario di chiusura:
152.50
-7.49
-4.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$163.09
Aprire:
$159.9
Volume 24 ore:
1.19M
Relative Volume:
0.62
Capitalizzazione di mercato:
$304.10B
Reddito:
$54.66B
Utile/perdita netta:
$13.58B
Rapporto P/E:
22.80
EPS:
7.0171
Flusso di cassa netto:
$16.05B
1 W Prestazione:
+4.02%
1M Prestazione:
+4.38%
6M Prestazione:
-3.12%
1 anno Prestazione:
+24.58%
Intervallo 1D:
$159.62
$160.93
Intervallo di 1 settimana:
$151.69
$164.48
Portata 52W:
$121.57
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Nome
Novartis Ag Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVS vs LLY, JNJ, ABBV, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Argus | Hold → Buy |
| 2026-01-27 | Iniziato | Citigroup | Buy |
| 2026-01-06 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-12-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-12 | Downgrade | Goldman | Neutral → Sell |
| 2025-08-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Downgrade | UBS | Buy → Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Underweight |
| 2025-02-04 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-09-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-09-03 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-19 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-23 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-09-25 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-26 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-05 | Aggiornamento | Stifel | Hold → Buy |
| 2022-09-15 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-05-09 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Ripresa | Citigroup | Buy |
| 2021-12-14 | Downgrade | Redburn | Buy → Neutral |
| 2021-12-06 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Iniziato | Bernstein | Mkt Perform |
| 2021-03-10 | Downgrade | Argus | Buy → Hold |
| 2021-02-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2020-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-03-10 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-04-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-04-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-10 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2018-05-25 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Reiterato | Leerink Partners | Outperform |
| 2017-12-06 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Iniziato | Liberum | Buy |
Mostra tutto
Novartis Ag Adr Borsa (NVS) Ultime notizie
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - GlobeNewswire Inc.
Novartis stock slips as Jefferies and UBS stay neutral after Hybrozyme deal - ad-hoc-news.de
Novartis Up 5.6% After MS Pill Gains $3 Billion Sales Potential - ts2.tech
Novartis stock gains as remibrutinib MS data offsets CAR T trial pause - ad-hoc-news.de
Why Is Novartis Stock Soaring Tuesday?Novartis (NYSE:NVS) - Benzinga
Novartis shares rise after multiple sclerosis drug hits late-stage trial goals - Investing.com
Novartis stock steadies after pause of autoimmune cell therapy trials - ad-hoc-news.de
Novartis stock trades mixed as investors weigh post-earnings outlook - ad-hoc-news.de
Novartis stock trades below consensus target as post-earnings digestion continues - ad-hoc-news.de
Novartis stock holds steady as investors digest latest 2026 earnings and guidance - ad-hoc-news.de
Novartis stock holds steady as oncology and Alzheimer’s pipeline draws attention - ad-hoc-news.de
Novartis AGADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Novartis stock edges lower as investors look past recent FDA win - ad-hoc-news.de
Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors - ChartMill
Novartis stock extends its rally as investors weigh valuation and cardiovascular data plans - Ad-hoc-news.de
Novartis stock holds above $150 after orphan drug update - Ad-hoc-news.de
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Novartis stock holds above $150 as orphan drug milestone and earnings strength support valuation - Ad-hoc-news.de
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Novartis AG Sponsored ADR Revenue Breakdown – MUN:NOTA - TradingView
Novartis stock slips after UK patent win and strong Q2 2026 - Ad-hoc-news.de
Novartis stock slips from recent highs as investors digest latest quarter - Ad-hoc-news.de
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis (NYSE:NVS): A Top Dividend Stock with Strong Fundamentals and Sustainable Payouts - ChartMill
Weekly Recap: Novartis Q2 net sales up ~1–3% and Entresto 50% sales drop - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Revenue Breakdown – BCBA:NVSB - TradingView
Novartis AG Sponsored ADR Revenue Breakdown – SWB:NOTA - TradingView
Novartis stock trades steady as Q1 2026 revenue grows and Cosentyx expansion supports outlook - Ad-hoc-news.de
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline - Sahm
Novartis stock trades steady as Q2 2026 results highlight solid specialty medicines growth - Ad-hoc-news.de
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Novartis ADR earnings beat by $0.23, revenue topped estimates - Investing.com Canada
Novartis AG Stock (NVS) Moved Up by 3.42% on Jul 21: Key Drivers Unveiled - TradingKey
Novartis second quarter sales rise 3% to $14.4 billion - grafa.com
Earnings call transcript: Novartis tops Q2 2026 forecasts as shares rise - Investing.com
Novartis (NYSE: NVS) Q2 2026: key drugs surge while net debt jumps - Stock Titan
Novartis (NYSE:NVS) Faces A Defining Pipeline Test - Kalkine Media
NVS Stock Quote Price and Forecast - CNN
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Sahm
Novartis stock holds steady as pipeline and global reach underpin long-term growth - Ad-hoc-news.de
Stada Denied Speedy Trial In Novartis Heart Drug Patent Case - law360.com
Novartis highlights drug pipeline strength as global healthcare demand grows - Ad-hoc-news.de
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Sahm
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - Barchart.com
Why Does Novartis AG-Sponsored ADR (NYSE:NVS) Track the NYSE Composite? - Kalkine Media
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout - ChartMill
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition - sharewise.com
Novartis to acquire Myricx Bio for $1.5 billion - grafa.com
10 Newly Overvalued Stocks this Week - Morningstar
Novartis Ag Adr Azioni (NVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):